MacroGenics, Inc. (MGNX): Price and Financial Metrics


MacroGenics, Inc. (MGNX): $6.90

-0.02 (-0.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MGNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MGNX POWR Grades

  • Growth is the dimension where MGNX ranks best; there it ranks ahead of 98.96% of US stocks.
  • MGNX's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • MGNX ranks lowest in Stability; there it ranks in the 4th percentile.

MGNX Stock Summary

  • Of note is the ratio of MACROGENICS INC's sales and general administrative expense to its total operating expenses; just 9.23% of US stocks have a lower such ratio.
  • As for revenue growth, note that MGNX's revenue has grown -19.83% over the past 12 months; that beats the revenue growth of just 8.79% of US companies in our set.
  • The volatility of MACROGENICS INC's share price is greater than that of 90.99% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MGNX, based on their financial statements, market capitalization, and price volatility, are CLLS, ALT, PIRS, LPTX, and GRTS.
  • Visit MGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.macrogenics.com.

MGNX Valuation Summary

  • In comparison to the median Healthcare stock, MGNX's price/earnings ratio is 108.19% lower, now standing at -1.9.
  • MGNX's price/earnings ratio has moved up 187.8 over the prior 111 months.

Below are key valuation metrics over time for MGNX.

Stock Date P/S P/B P/E EV/EBIT
MGNX 2022-11-25 3.9 3.0 -1.9 -1.6
MGNX 2022-11-23 4.1 3.1 -2.0 -1.7
MGNX 2022-11-22 4.1 3.1 -2.0 -1.7
MGNX 2022-11-21 4.2 3.2 -2.1 -1.7
MGNX 2022-11-18 4.3 3.2 -2.1 -1.8
MGNX 2022-11-17 4.3 3.3 -2.1 -1.8

MGNX Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -239.78%.
  • The year over year cash and equivalents growth rate now stands at -78.34%.
  • Its year over year price growth rate is now at -78.25%.
Over the past 70 months, MGNX's revenue has gone up $1,109,000.

The table below shows MGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 92.989 -170.588 -190.582
2022-06-30 66.917 -175.961 -218.655
2022-03-31 71.667 -172.49 -217.286
2021-12-31 77.447 -143.83 -202.115
2021-09-30 115.991 -95.054 -146.18
2021-06-30 118.582 -105.936 -129.337

MGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MGNX has a Quality Grade of C, ranking ahead of 36.14% of graded US stocks.
  • MGNX's asset turnover comes in at 0.284 -- ranking 156th of 681 Pharmaceutical Products stocks.
  • SRNE, CNCE, and VBLT are the stocks whose asset turnover ratios are most correlated with MGNX.

The table below shows MGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.284 0.985 -0.809
2021-06-30 0.294 1.000 -0.724
2021-03-31 0.285 1.000 -0.860
2020-12-31 0.312 1.000 -0.859
2020-09-30 0.242 1.000 -1.055
2020-06-30 0.248 1.000 -1.081

MGNX Price Target

For more insight on analysts targets of MGNX, see our MGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.25 Average Broker Recommendation 1.45 (Moderate Buy)

MGNX Stock Price Chart Interactive Chart >

Price chart for MGNX

MGNX Price/Volume Stats

Current price $6.90 52-week high $18.25
Prev. close $6.92 52-week low $2.13
Day low $6.46 Volume 739,737
Day high $6.96 Avg. volume 927,260
50-day MA $4.98 Dividend yield N/A
200-day MA $5.36 Market Cap 424.18M

MacroGenics, Inc. (MGNX) Company Bio


Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.


MGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGNX Latest Social Stream


Loading social stream, please wait...

View Full MGNX Social Stream

Latest MGNX News From Around the Web

Below are the latest news stories about MACROGENICS INC that investors may wish to consider to help them evaluate MGNX as an investment opportunity.

Here's How to Find Cheap Stocks Under $10 to Buy for December

Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...

Yahoo | November 29, 2022

Why Shares of MacroGenics Were Dropping Tuesday

Shares of MacroGenics (NASDAQ: MGNX) were down more than 18% in early trading on Tuesday. Last week, the company's shares rose when it got word that a $60 million milestone payment was coming its way after the Food and Drug Administration approved the Biologics License Application (BLA) for teplizumab to delay the onset of type 1 diabetes. MacroGenics developed the drug, but it was purchased by Provention Bio in 2018.

Yahoo | November 22, 2022

H.C. Wainwright Sticks to Their Buy Rating for MacroGenics (MGNX)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on MacroGenics (MGNX - Research Report), with a price target of $12.00. The company's shares closed last Friday at $6.48.According to TipRanks, Burns is an analyst with an average return of -24.1% and a 22.68% success rate. Burns covers the Healthcare sector, focusing on stocks such as MacroGenics, Neoleukin Therapeutics, and Y-Mabs Therapeutics.MacroGenics has an analyst consensus of Strong Buy, with a price target consensus of $13.71, which is an 111.57% upside from current levels. In a report released on November 14, BMO Capital also upgraded the stock to a Buy with a $16.00 price target.

Austin Angelo on TipRanks | November 21, 2022

Rockville’s MacroGenics scores $60M from Provention Bio’s FDA approval

Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October. MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018. As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.

Yahoo | November 18, 2022

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.

Yahoo | November 18, 2022

Read More 'MGNX' Stories Here

MGNX Price Returns

1-mo 42.27%
3-mo 62.74%
6-mo 106.59%
1-year -60.18%
3-year -25.81%
5-year -64.41%
YTD -57.01%
2021 -29.79%
2020 110.11%
2019 -14.33%
2018 -33.16%
2017 -7.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8538 seconds.